Based on a filing on October 23 in Massachusetts federal court, Roche, the Swiss pharmaceutical giant, has reached a settlement in a patent lawsuit against Biogen, which happens to be a U.S. biotech firm. The lawsuit was concerning Biogen’s biosimilar variant of Roche’s incredibly successful rheumatoid Arthritis Drug, Actemra. Roche, along with its affiliates, Genentech […]

The post Roche – Biogen Settle US Patent Law Suit For Arthritis Drug first appeared on World Pharma Today.